With the aim of evaluating the effects on blood pressure, platelet function and insulin sensitivity of the dihydropiridines lacidipine and nifedipine GITS, a parallel double-blind study was carried out in a group of 20 patients with mild to moderate essential hypertension. They received a placebo for 4 weeks; then were divided at random into two groups of 10 patients each. Nifedipine GITS, 30 mg and lacidipine, 4 mg, were given during 16 weeks of active treatment. Blood pressure and heart rate were measured at the clinic in supine, sitting and standing positions, 24 ؎ 1 h after the last dose. After the placebo and active phases were carried out, a platelet aggregation test was performed to determine platelet malondialdehyde production and a tolerance to 100 g of glucose by measuring glucaemia and plasma insulin.
Introduction
Calcium antagonists reduce arterial blood pressure by relaxing the smooth arteriole muscle and diminishing peripheral vascular resistance. 1 The pharmacodynamic and pharmacokinetic characteristics of different calcium antagonists vary considerably. 2, 3 According to the agent, the effect may last from a short to a very long time period, which has important clinical implications in the protection of the hypertensive patient throughout the 24 h period. 4, 5 Lacidipine, a dihydropyridine derived calcium antagonist, has relative prolonged action: the administration of 4 mg once a day reduces blood pressure over 24 h with one, daily dosage. 6, 7 In comparison with short-acting dihydropyridine drugs which resulted in a fluctuation in blood pressure and some side effects associated with rapid vasodilatation and sympathetic activation. 3, 8, 9 Regular nifedipine requires three or four doses per day to have a sustained effect over 24 h. The osmotic slow release formulation (GITS) has been developed to allow administration in one dose per day. 10 Nifed- ipine GITS allows the drug to be released through the intestinal tract over a long enough period to maintain stable plasma levels for 24 h with a single daily dose.
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Platelets play an important role in the atherosclerotic process in the hypertensive patient, not only in initial vessel damage but also in the process of acute lumen obstruction. 12, 13 Eicosanoids produced by platelets are important to regulate their activity. 12 Either tromboxano A-2 or malondialdehyde production can be determined to estimate arachidonic acid and prostaglandin metabolism at the platelet level.
14 Antihypertensive treatment should ideally not only modify blood pressure to control level, but also contribute to modify other risk factors.
The aim of the present study was to evaluate the effects on blood pressure, platelet aggregation and insulin and glucose levels by lacidipine and nifedipine GITS given once daily, in a parallel, doubleblind, randomised study on patients with mild to moderate hypertension.
Patients and methods
Twenty patients with mild to moderate hypertension, who also fulfilled pre-established selection criteria, were the subjects of this study. The patients average age was 50 ± 2.3 years. The patient's characteristics can be seen in Table 1 .
All patients initially received placebo tablets in a simple blind test for 4 weeks. Then patients were allocated at random either in lacidipine or nifedipine GITS groups; 10 patients to, each group. Patients received two tablets daily (one placebo and one active tablet), taken between 7 and 8 am over the 16-week treatment.
Patients were evaluated every 2 weeks at the hypertension clinic. Systolic and diastolic blood pressure were measured using phase I and V Korotkoff sounds in supine, seated and standing positions. Heart rate was taken in the same positions. All measurements were carried out 24 ± 1 h from the last dose of the tablets. Side effects were recorded. Compliance of treatment was assessed by counting tablets, every visit.
Platelet function evaluation
Platelet aggregation: At the end of the placebo and active medication phases a 20-ml antecubital blood sample was taken and mixed with a solution of sodium citrate at 3.8% in a ratio of 9:1. The blood was centrifuged to obtain platelet-rich and plateletpoor plasma. The concentration of platelet-rich plasma was adjusted in every case to 300 000 platelets/L using the platelet-poor plasma. Platelet aggregation test was carried out with a Biodata PAP-4 Aggregometer (Biodata Corporation, Hatboro, PA, USA) using the following proaggregation agents: Platelet-rich plasma, adjusted to 300 000 platelets/L was placed in the test tube with a magnetic agitator at a velocity of 1100 rotations per minute. The paper was allowed to run for a minute to check spontaneous aggregation after which the pro-aggregate agent was added and the test was allowed to run for 5 min. At the end of this period the percentage aggregation produced was measured. The test was repeated twice and the values averaged in each case. Measurement of platelet malondialdehyde production: Malondialdehyde was measured by the thiobarbituric acid methods, 15, 16 using N-ethylmaleimide (Sigma Chemical Co) as activator, at the end of placebo and active therapy. Venous blood was collected from the antecubital vein and mixed with 3.8% sodium citrate solution. The platelet-rich plasma and platelet-poor plasma were obtained as described previously. The platelet-rich plasma adjusted at 300 000 platelet/L, was divided into 2-ml aliquots and centrifuged at 250 g for 18 min to obtain platelet buttons. The supernatant was discarded.
Either 2 ml of N-ethylmaleimide (NEM) in 1 mM or 2 ml of isotonic saline were added, then incubated at 37°C for 60 min in a water bath. Malondialdehyde was determined using 2 ml of a mixer of thiobarbituric acid (0.53% in perchloric acid and 2.3% in PCA 7%, ratio 2:1).
The solution was heated in a boiling water bath for 15 min, cooled off to room temperature and centrifuged. The optical density was read at 534 nM in a Spectronic 20D (Milton Roy Company, USA) against a blank.
To calculate the malondialdehyde concentration, the molar coefficient of extinction was 1.47 × 10
.
The ratio MDA-basal (isotonic saline)/MDA-activated (NEM) was calculated as described by Makris et al. 16 
Statistical analysis
The data were grouped and the mean and standard error calculated. Statistical significance was obtained using the Student's t-test (P Ͻ 0.05, twotailed) for paired and unpaired data: as well as for the analysis of variance (ANOVA).
Results

Blood pressures and heart rate
In the lacidipine group supine blood pressures (systolic/diastolic) during the placebo were 168/103 mm Hg; after weeks 1 and 16 of active treatment blood pressure was reduced to 157/94 (P Ͻ 0.02) and 148/91 (P Ͻ 0.001), respectively. Statistical comparison between weeks 1 and 16 in active treatment was significant (Table 2 ).
In the nifedipine GITS group the results for the supine position were 165/105 mm Hg in the placebo phase, 140/90 mm Hg (P Ͻ 0.001) in the first week and 137/88 mm Hg after 16 weeks of treatment (P Ͻ 0.001). Statistical comparison between week 1 and week 16 showed equivalent results
In the supine position, the heart rate in the lacidipine group varied from 74 bpm to 82 bpm and to 75 bpm in the placebo phase between the first week and week 16 of active treatment (P Ͼ 0.05). In the nifedipine GITS group, heart rate changed from 73 bpm in the placebo phase to 84 and 77 bpm in the first and 16th weeks of active medication (P Ͼ 0.05). 
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Platelet aggregation
Platelet aggregation test during the study can be seen in Table 3 . Platelet aggregation induced by adenosine diphosphate (ADP) (10 M), adrenaline (10 M), and collagen (1.0 g/ml) at the end of the placebo phase were 89.2%, 82.2% and 93.2%, respectively; this changed to 86.2% (P Ͼ 0.05, NS), 68.9% (P Ͻ 0.05), and 90.4% (P Ͼ 0.05, NS) respectively at the end of active treatment in the lacidipine group of patients. In the nifedipine GITS group of patients, platelet aggregation changed from 90.8%, 86.1% and 89.3% to 87.9% (P Ͼ 0.05, NS), 78.4% (P Ͻ 0.05) and 86.4% (P Ͼ 0.05, NS) for the three inducers, at the same concentrations respectively.
Platelet malondialdehyde
The results of basal and activated malondialdehyde and the ratio MDA basal:activated can be seen in Table 4 , in the lacidipine group basal malondialdehyde was reduced in 41.8% (P Ͻ 0.01); MDA activated in 18.65% (NS) and the ratio basal:activated in 23.35% (P Ͻ 0.01).
In the nifedipine GITS group of patients, basal malondialdehyde production was reduced in 31.4% (P Ͻ 0.001), activated MDA in 16.19% (NS), and the ratio basal:activated in 16.78% (P = 0.07, NS). Both drugs were well tolerated, in the lacidipine group some patients complained of headache and one of dizziness; on nifedipine GITS two patients complained of headache and one patient of mild ankle oedema. Side effects were mild and tolerated by patients; no one dropped out from the study.
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Discussion
From the results obtained, both calcium antagonist drugs studied, nifedipine GITS and lacidipine administered in a single daily dose of 30 mg and 4 mg respectively, significantly reduced systolic and diastolic blood pressure in patients with mild to moderate hypertension. However, the speed of reduction on blood pressure was different with each drug. Nifedipine GITS reduced blood pressure to control levels after the first week of treatment; at the supine position the blood pressure at the end of the first week had decreased to 25/15 mm Hg in relation to placebo values, statistically equivalent to a reduction of 28/17 mm Hg obtained in week 16 (ANOVA test, P Ͼ 0.05, NS). However, lacidipine reduced blood pressure at the end of the first week to 11/9 mm Hg in relation to placebo values (P Ͻ 0.025). At the end of week 16 the decrease reached 20/12 mm Hg (P Ͻ 0.001). Thus a comparison of the results of the values of the different weeks of active medication according to ANOVA showed them to be statistically significant (P Ͻ 0.05), a slower and more progressive reduction of blood pressure being observable with lacidipine in comparison to nifedipine GITS.
A rapid reduction in blood pressure by vasodilatation induces sympathetic reflex discharge in the hypertensive patients, with release of catecholamines and increasing heart rate by stimulation of beta-1 adrenoceptors.
When regular nifedipine release is administered orally, a fast reduction in blood pressure is found in 20 min and maximum is reached in 1 h. But the effect does not last more than 8 h, 17 at the same time a significant increase in heart rate, indicating an immediate sympathetic discharge as a response to the decrease in peripheral vascular resistance. Leenen, 18 comparing the effect of nifedipine GITS to amlodipine, found that nifedipine GITS slightly but significantly increases levels of adrenaline, noradrenaline and renin serum, indicating a neurohumoral response even in long term treatment with this drug prepared for gradual long-term release, while amlodipine did not produce this effect. Lacidipine, on the other hand, has been reported not to modify catecholamine levels, renin serum levels or aldosterone. 18, 19 In the present study lacidipine increased heart rate in the standing position by 9 bpm (P Ͼ 0.05, NS) in the first week of treatment and by 3 bpm on average by the end of week 16. This was not statistically significant in either case. The nifedipine GITS increased heart rate by 11 bpm both in the first and 16th week of active treatment (P Ͻ 0.02); indicating a slight sympathetic activation, as reported by Leenen. 18 These results show that nifedipine GITS, in spite of being a calcium antagonist with a short half-life and short duration of action when it is prepared to osmotic release, maintained its effect for 24 h, in the same way that lacidipine does. 20 In relation to platelet function, the present study showed that both drugs induced a reduction in platelet aggregation induced by adrenaline at high concentrations but not with ADP or collagen. Calcium antagonists are known to share the common property of inhibiting the entrance of calcium into the cell, 21 and in higher concentrations may interfere with storage and release of calcium intracellularly. In 1981 Ideka 22 demonstrated that verapamil reduced platelet aggregation, especially at low concentrations of ADP and adrenaline when patients took 240 mg/daily of the drug. Dihydropyridine derivatives have also been shown to have an effect on platelet aggregation, especially in in vitro tests, that is, when concentrations of the agent are added to the test tube before the inductors agent. Thus, nifedipine 23 and nitrendipine 24 reduce the platelet aggregation in vitro at higher concentrations than those used in antihypertensive treatment. Other dihydropyridine derivatives, such as amlodipine, reduce platelet aggregation during antihypertensive therapy, as reported by Hernandez-Hernandez et al 25 when in a group of 12 patients with essential hypertension a 20-45% reduction in platelet aggregation was obtained using the same inducers tested in the present study.
Activation of platelets can be evaluated by the measurement of platelet malondialdehyde production, in basal conditions or after the stimulation of arachidonic acid metabolic pathway. Both drugs, lacidipine and nifedipine GITS, induced a reduction in the production of both basal and activated malondialdehyde; as well as in the ratio MDA basal:activated. Lacidipine reduced these values by 41.8%, 16.65% and 23.35% respectively. Meanwhile nifedipine GITS did so by 31.4%, 16.19% and 16.78% respectively. There was no statistically significant difference between the groups, either for placebo values or at the end of active medication. This would indicate that both drugs have a similar effect on platelet malondialdehyde production, indicating these agents tend to normalise the balance of eicosanoids, especially in the production of thromboxane A 2 which has been reported to be high in patients with arterial hypertension. 26 Other dihydropyridine calcium antagonists, such as amlodipine, reduce platelet aggregation and malondialdehyde production, in contrast to enalapril. 27 
